Israel - hebraisk - Ministry of Health

novartis israel ltd - deferoxamine mesylate - אבקה להמסה להזרקה\אינפוזיה - deferoxamine mesylate 0.5 g/vial - deferoxamine

Israel - hebraisk - Ministry of Health

dover medical & scientific equipment ltd, israel - factor viii (human); von willebrand factor - אבקה וממס להכנת תמיסה להזרקה - von willebrand factor 1000 iu/vial; factor viii (human) 1000 iu/vial - coagulation factor viii

Israel - hebraisk - Ministry of Health

dover medical & scientific equipment ltd, israel - factor viii (human); von willebrand factor - אבקה וממס להכנת תמיסה להזרקה - von willebrand factor 500 iu/vial; factor viii (human) 500 iu/vial - coagulation factor viii

Israel - hebraisk - Ministry of Health

novartis israel ltd - deferoxamine mesylate - אבקה להמסה להזרקה\אינפוזיה - deferoxamine mesylate 0.5 g/vial - deferoxamine

Israel - hebraisk - Ministry of Health

sanofi - aventis israel ltd - imiglucerase 200 u/vial - powder for solution for infusion - imiglucerase - for the long term enzyme replacement therapy for patients with a confirmed diagnosis of type 1 gaucher disease that results in one or more of the following conditions: - anemia , - thrombocytopenia , - bone disease , - hepatomegaly or splenomegaly.

Israel - hebraisk - Ministry of Health

sanofi israel ltd - agalsidase beta - אבקה להכנת תמיסה מרוכזת לעירוי - agalsidase beta 35 mg/vial - agalsidase beta - agalsidase beta - fabrazyme is indicated for use as long-term enzyme replacement therapy in patients with a confirmed diagnosis of fabry disease. (alfa - galactosidase a deficiency).

Israel - hebraisk - Ministry of Health

pfizer pharmaceuticals israel ltd - taliglucerase alfa - אבקה להכנת תמיסה לאינפוזיה - taliglucerase alfa 200 u/vial - taliglucerase alfa - taliglucerase alfa - elelyso (taliglucerase alfa ) for injection is a hydrolytic lysosomal glucocerebroside - specific enzyme indicated for long - term enzyme replacement therapy (ert) for adults with a confirmed diagnosis of type 1 gaucher disease.

Israel - hebraisk - Ministry of Health

glaxo smith kline (israel) ltd - epoprostenol as sodium - אבקה להכנת תמיסה לאינפוזיה - epoprostenol as sodium 1.5 mg/vial - epoprostenol - epoprostenol - flolan is indicated for the long-term intravenous treatment of primary arterial pulmonary hypertension and arterial pulmonary hypertension associated with the scleroderma spectrum of disease in nyha class iii and class iv patients who do not respond to conventional therapy.

Israel - hebraisk - Ministry of Health

glaxo smith kline (israel) ltd - epoprostenol as sodium - אבקה להכנת תמיסה לאינפוזיה - epoprostenol as sodium 0.5 mg/vial - epoprostenol - epoprostenol - flolan is indicated for the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in nyha class iii and class iv patients who do not respond to conventional therapy.

Israel - hebraisk - Ministry of Health

teva medical marketing ltd. - coagulation factor viii recombinant 250 iu/vial - powder for solution for injection - coagulation factor viii - the use of recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).recombinate is also indicated in the perioperative management of patients with haemophilia a. recombinate is appropriate for use in children of all ages including the newborn. (safety and efficacy studies have been performed in both previously treated and previously untreated children). the product in not suitable for the treatment of von willebrand's disease.